Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MD1003 in Progressive Multiple Sclerosis (SPI2)
NCT02936037Phase 3Terminated
- Sponsor
- MedDay Pharmaceuticals
- Start
- Dec 2016
- Primary completion
- Nov 2019
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Placebo Arm with MD1003 Arm (2 arms). Primary endpoint: Proportion of Patients Improved on Either Expanded Disability Status Scale (EDSS) or Time to Walk 25 Feet (TW25) at 15 months. Started Dec 2016; status: terminated.
02
Drugs
biotin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02936037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02936037.